Digitalis Glycosides

Danger with simultaneous use of calcium salts and digitalis drugs. A digitalized patient should not receive IV calcium unless indications are clearly defined.

Both slow atrioventricular conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Patients receiving digitalis should be observed carefully for development of cardiac arrhythmias.

Amphotericin B-induced hypokalemia may potentiate digitalis toxicity. Monitor serum potassium levels and cardiac function.

Both slow atrioventricular conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Both drugs slow atrioventricular conduction and decrease heart rate; concomitant use increases bradycardia risk.

Patients may be at increased risk of arrhythmias due to hypokalemia induced by corticosteroids.

Both slow atrioventricular conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Concomitant use may have additive effects resulting in hypotension and/or marked bradycardia.

Both slow AV conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Both digitalis and beta-blockers slow AV conduction and decrease heart rate. Concomitant use increases risk of bradycardia.

Concomitant use with beta-adrenergic blocking agents may have additive effects in prolonging atrioventricular conduction time.

Hypercalcemia may precipitate cardiac arrhythmias in patients on digitalis therapy; careful dosage determination required.

Hypercalcemia resulting from calcitriol use may precipitate cardiac arrhythmias in digitalis-treated patients; dosage must be determined with care.

Digitalis glycosides and carvedilol both slow atrioventricular conduction and decrease heart rate, increasing bradycardia risk.

Cholestyramine may delay or reduce digitalis absorption; discontinuance poses hazard if digitalis was titrated to maintenance level during cholestyramine use.

Cholestyramine may reduce digitalis absorption; discontinuance poses hazard if drug was titrated to maintenance level during concurrent use.

Cholestyramine may reduce digitalis absorption; discontinuance could pose hazard if drug was titrated to maintenance level during concurrent use.

Additive effects on sinus node function and AV nodal conduction, potentially causing bradycardia and AV block. Monitor heart rate.

Potential for additive effects such as bradycardia and AV block. Caution is warranted.

Patients may be at risk of arrhythmias due to hypokalemia induced by corticosteroids.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia induced by dexamethasone.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to dexamethasone-induced hypokalemia.

Additive effects in prolonging AV conduction when used concomitantly with diltiazem hydrochloride.

Concurrent use may increase risk for hypotension, bradycardia, and heart failure due to impaired cardiac contractility and conduction.

Doxercalciferol-induced hypercalcemia can potentiate the risk of digitalis toxicity. Monitor for signs and symptoms of digitalis toxicity.

May increase possibility of arrhythmias when given with ephedrine. Carefully monitor patients on cardiac glycosides.

Cardiac glycosides potentiate arrhythmogenic effects of epinephrine.

Cardiac glycosides that increase arrhythmogenic potential of epinephrine. Monitor for cardiac arrhythmias.

Enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia. Monitor serum potassium levels and use potassium supplements if necessary.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to corticosteroid-induced hypokalemia.

Both digitalis glycosides and labetalol slow atrioventricular conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Both digitalis glycosides and labetalol slow AV conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Levothyroxine sodium may reduce the therapeutic effects of digitalis glycosides. Serum digitalis levels may decrease when patient becomes euthyroid, necessitating an increase in digitalis glycoside dose.

Therapeutic effects of digitalis glycosides may be reduced by levothyroxine. Serum digitalis glycoside levels may decrease when hypothyroid patient becomes euthyroid, necessitating dose increase.

Monitor toxicity when lidocaine is used in patients with digitalis toxicity accompanied by supraventricular arrhythmia and/or atrioventricular block.

Thyroid preparations may potentiate toxic effects of digitalis. Increased metabolic rate from thyroid hormone replacement increases digitalis dosage requirements.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to corticosteroid-induced hypokalemia.

Patients may be at risk of arrhythmias due to hypokalemia caused by corticosteroids.

Patients may be at risk of arrhythmias due to hypokalemia from corticosteroid use.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia from corticosteroid use.

Diuretic-induced hypokalemia can increase myocardial sensitivity to digitalis, resulting in serious arrhythmias.

Concomitant use increases risk of bradycardia. Both agents slow atrioventricular conduction and decrease heart rate.

Digitalis glycosides slow atrioventricular conduction and decrease heart rate; concomitant use with metoprolol increases bradycardia risk.

Concomitant use with metoprolol succinate ER slows AV conduction and decreases heart rate, increasing bradycardia risk.

Digitalis slows atrioventricular conduction and decreases heart rate; concomitant use with metoprolol increases risk of bradycardia.

Concomitant use increases risk of bradycardia due to additive negative chronotropic effects.

Concomitant use with metoprolol can increase risk of bradycardia due to slowed atrioventricular conduction and decreased heart rate.

Both digitalis glycosides and nadolol slow atrioventricular conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Both slow atrioventricular conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Both slow atrioventricular conduction and decrease heart rate, increasing risk of bradycardia when used concomitantly.

Paricalcitol-induced hypercalcemia can potentiate digitalis toxicity risk. Monitor for digitalis toxicity signs and increase serum calcium monitoring frequency.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia from concurrent corticosteroid use.

Patients on digitalis glycosides are at increased risk of arrhythmias due to corticosteroid-induced hypokalemia.

Both digitalis glycosides and propranolol slow atrioventricular conduction and decrease heart rate, increasing risk of bradycardia.

Parenteral magnesium should be administered with extreme caution to patients receiving digitalis preparations.

Absorption of calcium-containing solution may increase digitalis effects and lead to serious or fatal cardiac arrhythmia.

Hypokalemia from sodium polystyrene sulfonate may exaggerate digitalis toxicity, including ventricular arrhythmias and A-V nodal dissociation.

Concomitant use may have additive effects in prolonging atrioventricular conduction time. Caution should be used due to possible atrioventricular conduction disturbances.

Patients may be at increased risk of arrhythmias due to hypokalemia induced by corticosteroids.

Concurrent use may induce hypokalemia and potentiate digitalis toxicity. Serum potassium levels should be closely monitored.

Digitalis may influence serum electrolytes when used with chlorthalidone, requiring monitoring for warning signs of electrolyte imbalance.

Monitor heart rate in patients receiving clonidine concomitantly with digitalis due to effects on sinus node function or AV nodal conduction.

Increased ectopic pacemaker activity can occur when pseudoephedrine is used with digitalis. Exercise caution when used concomitantly.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to dexamethasone-induced hypokalemia.

May have additive effects in prolonging atrioventricular conduction time when used with beta-adrenergic blocking agents.

May have additive effects in prolonging atrioventricular conduction time.

May partially counteract the anticoagulant action of heparin. Careful monitoring recommended.

Patients may be at increased risk of arrhythmias due to hypokalemia from corticosteroid use.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia caused by corticosteroids.

Digitalis induces renal losses of magnesium.

Digitalis induces renal losses of magnesium, potentially leading to hypomagnesemia.

Serum digitalis levels may increase when hyperthyroid patients become euthyroid; reduced digitalis dosage may be needed.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia induced by corticosteroids.

Isolated reports of elevated digoxin levels with possible interaction. Monitor digoxin levels when initiating, adjusting, or discontinuing nifedipine.

May produce unfavorable interactions with potassium supplements, risk of hyperkalemia.

Serum digitalis levels may increase when hyperthyroid patients on stable digitalis therapy become euthyroid. A reduced dose of digitalis glycosides may be needed.

Both slow atrioventricular conduction and decrease heart rate; concomitant use increases risk of bradycardia.

Concomitant use may have additive effects in prolonging atrioventricular conduction time.

May have additive effects in prolonging atrioventricular conduction time when used concomitantly with timolol.

Concomitant use may have additive effects in prolonging atrioventricular conduction time.

Patients may be at increased risk of arrhythmias due to corticosteroid-induced hypokalemia.

Prazosin has been administered without adverse drug interaction with digitalis in limited clinical experience.

Administered without adverse drug interaction in limited clinical experience.

Verapamil has been used concomitantly with digitalis without evidence of serious negative drug interactions.